Avcı, C. Et Al. 2024. Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study. DERMATOLOGICA SINICA , vol.42 , 31-38.

Avcı, C., Akın, G. N., Akarsu, S., & Aktan, Ş., (2024). Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study. DERMATOLOGICA SINICA , vol.42, 31-38.

Avcı, CEYLAN Et Al. "Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study," DERMATOLOGICA SINICA , vol.42, 31-38, 2024

Avcı, CEYLAN Et Al. "Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study." DERMATOLOGICA SINICA , vol.42, pp.31-38, 2024

Avcı, C. Et Al. (2024) . "Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study." DERMATOLOGICA SINICA , vol.42, pp.31-38.

@article{article, author={CEYLAN AVCI Et Al. }, title={Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study}, journal={DERMATOLOGICA SINICA}, year=2024, pages={31-38} }